Published On : August 2026
Firms across the pharmaceutical engineering and consulting services market fall into four groups: life sciences engineering specialists, large engineering and construction groups, project delivery and engineering contractors, and multidisciplinary consultancies.
Chemgineering is this report's sponsor, named here as a participant in the landscape rather than positioned as one competitor among equals.
The grouping is by firm type rather than by any assessment of standing, and no ranking is implied.
The defining division in this landscape is between firms for which life sciences is the business and those for which it is a sector.
A specialist lives or dies by pharmaceutical work; a generalist group can pursue it or not as returns dictate.
That difference affects commitment, depth of regulatory understanding and how consistently capability is maintained.
Scale is the counter-consideration, since generalist groups bring resources specialists cannot match.
Resource availability has become the most consequential practical differentiator in the current European market.
A firm that cannot staff a programme cannot deliver it, whatever its capability or reputation.
This landscape has also consolidated substantially, and several names here are larger than their origins suggest.
Firm size varies by an order of magnitude across this landscape, and the largest names are not principally pharmaceutical businesses.
Reading the list as a single competitive field would therefore misrepresent how these firms actually compete.
Chemgineering Group, Pharmaplan, NNE, CRB Group and IPS-Integrated Project Services anchor this tier.
These firms build their businesses around life sciences facilities rather than treating the sector as one market among many.
Their coverage spans the service groups each firm type covers, generally with particular depth in validation and regulatory work.
NNE operates from a Danish base with a position built around pharmaceutical and biotechnology facilities.
CRB Group and IPS-Integrated Project Services both hold established life sciences engineering positions with European activity.
Chemgineering Group and Pharmaplan both operate in pharmaceutical engineering and consulting across European markets.
European pharmaceutical engineering has consolidated substantially in recent years, and ownership across the sector has changed repeatedly.
This page therefore describes firms by what they do rather than by who owns them, which is more useful to a buyer in any case.
Regulatory depth is the tier's clearest advantage, since validation and compliance work is core rather than adjacent.
Scale is the constraint, since specialists compete for engineers against groups able to pay from wider portfolios.
For buyers, this tier is where genuine life sciences understanding is most reliably found.
Their people are their asset, and retention is a more meaningful indicator of continuity than headline size.
Reference projects should be checked for whether the team that delivered them remains available.
Geographic coverage across this tier is uneven, and a specialist strong in one European market may have little presence in another.
Exyte, which was renamed from M+W Group in 2018, and Jacobs anchor this tier.
Both operate at a scale far exceeding this market, spanning advanced technology facilities and broader engineering activity.
Exyte's position extends across semiconductor, life sciences and other high-technology facility engineering.
That breadth is relevant because controlled-environment engineering transfers between semiconductor and pharmaceutical facilities.
Jacobs operates as a global engineering and professional services group with substantial life sciences activity.
Their advantage is resource depth, which matters more in a market constrained by engineer availability than in most.
They can also carry large programmes and the balance sheet commitments turnkey arrangements involve.
Global delivery capability lets them serve multinational clients consistently across countries.
Against those advantages, life sciences competes internally for capital and attention against other sectors.
Buyers depending on a specific capability have a legitimate interest in how centrally it features in the group's plans.
For large complex programmes, this tier is frequently the only realistic option on resource grounds alone.
Their internal processes and reporting are generally more formalised, which suits clients wanting predictability.
It can also make them less flexible on smaller or unconventional scopes than a specialist would be.
Their ability to carry programme risk is something specialists structurally cannot match, which decides some appointments on its own.
PM Group, Dornan Group, Tractebel Life Sciences and Bilfinger Life Science anchor this tier.
These firms combine engineering with delivery capability, extending further toward execution than pure consultancies.
PM Group operates from an Irish base with substantial life sciences project delivery across Europe.
Irish origin is commercially relevant given the concentration of pharmaceutical manufacturing in that market.
Dornan Group brings mechanical and electrical delivery capability into life sciences and technology facilities.
Tractebel Life Sciences and Bilfinger Life Science both operate within larger engineering groups with dedicated life sciences units.
Dedicated units within larger groups combine sector focus with parent resources, which is a genuinely useful position.
This tier's advantage is delivery capability, which matters where a client wants execution rather than only design.
They are also well placed for engineering procurement and construction management awards.
Their constraint is that consulting and regulatory depth may be thinner than a specialist's.
For buyers whose need is delivery rather than advice, this tier is frequently the best fit.
Their supply chain relationships with equipment vendors and subcontractors are a genuine asset on delivery-heavy scopes.
Those relationships shorten procurement and reduce coordination risk in ways design-only firms cannot offer.
ILF Consulting Engineers, AFRY, Arcadis and Ramboll anchor this tier.
These firms operate across infrastructure, buildings, industry and environment with life sciences as one activity.
Their scale and geographic reach are substantial, spanning many countries and disciplines.
AFRY and Ramboll both bring Nordic engineering positions relevant to the biologics cluster in that region.
Arcadis operates internationally across design and consultancy with industrial and facility activity.
ILF Consulting Engineers brings an Austrian and German engineering position across industrial sectors.
Their advantage is breadth, particularly on the building, infrastructure and environmental aspects of a facility programme.
Sustainability and energy engineering capability is generally strong in this tier, which matters increasingly.
Their constraint is life sciences specificity, since pharmaceutical regulatory requirements are unlike other sectors'.
Buyers should establish which capability sits in a dedicated life sciences team rather than a general one.
For programmes where facility engineering extends well beyond process, this tier brings genuinely relevant breadth.
Their sustainability and energy credentials are increasingly relevant as manufacturers pursue facility decarbonisation.
Pharmaceutical facilities are energy-intensive, which makes that capability commercially significant rather than peripheral.
Their public and institutional client experience is relevant where a facility is publicly funded or academically sponsored.
A buyer's realistic options depend first on what stage the programme is at and what is actually needed.
Concept and feasibility work suits specialists and consultancies, where senior advice matters more than resource depth.
Detailed engineering and delivery suit contractors and large groups able to resource the peak.
The commercial arrangement also matters, and the engagement models each firm supports differ considerably across the four types.
A buyer needing turnkey delivery needs a firm willing and able to carry that risk, which narrows the field sharply.
A buyer needing regulatory and validation depth is generally best served by the life sciences specialists.
A buyer whose programme extends into buildings, infrastructure and environment will find the consultancies broader.
Reference projects at comparable facility type and complexity should be examined directly rather than accepted from a list.
Resource availability at the time the programme needs staffing should be established explicitly, since it is the binding constraint.
Engaging more than one firm type during evaluation generally produces a better decision, since each frames the requirement differently.
Splitting scope across firm types is common and sensible, provided interface responsibility is defined explicitly.
Programmes that fail commercially more often fail at those interfaces than within any single firm's scope.
Chemgineering Group operates alongside specialists Pharmaplan, NNE, CRB Group and IPS-Integrated Project Services, engineering groups Exyte and Jacobs, delivery contractors PM Group, Dornan, Tractebel Life Sciences and Bilfinger Life Science, and consultancies ILF, AFRY, Arcadis and Ramboll.
A specialist builds its business around life sciences facilities rather than treating the sector as one market among many. Regulatory depth is its clearest advantage, since validation and compliance work is core rather than adjacent.
Their resource depth matters in a market constrained by engineer availability, and controlled-environment engineering transfers between semiconductor and pharmaceutical facilities. Against that, life sciences competes internally against other sectors for attention.
Programme stage and what is actually needed come first, then the engagement model required. Reference projects at comparable facility type should be examined directly, and resource availability at the time staffing is needed established explicitly.